Menu Search
Equities

Shield Therapeutics PLC

SHIEF:QXE

Shield Therapeutics PLC

Actions
  • Price (USD)0.20
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-76.47%
  • Beta--
Data delayed at least 15 minutes, as of May 18 2022.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Shield Therapeutics plc is a United Kingdom-based commercial stage specialty pharmaceutical company. The Company specializes in the development and commercialization of late-stage pharmaceuticals which address areas of unmet medical need. The Company's lead product, Feraccru/Accrufer (ferric maltol), is a stable, non-salt-based oral therapy for adults with iron deficiency with or without anemia. Ferric maltol is approved in the United States, European Union, United Kingdom and Switzerland for the treatment of iron deficiency with or without anemia in adults. Its pipeline product candidate, PT20, is an iron-based phosphate binder that has the potential to treat patients with hyperphosphatemia related to dialysis or non-dialysis dependent chronic kidney disease (CKD). PT20 has completed its Phase II pivotal study. Its subsidiaries include Shield Therapeutics (DE) GmbH, Shield TX (UK) Limited, Phosphate Therapeutics Limited, and others.

  • Revenue in GBP (TTM)1.95m
  • Net income in GBP-13.04m
  • Incorporated2015
  • Employees16.00
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.